|Title:||Elimination of lymphatic filariasis in the South-East Asia Region : Report of the ninth meeting of the regional programme review group (RPRG) Yangon, Myanmar|
|Authors:||World Health Organization, Regional Office for South-East Asia|
|Publisher:||WHO Regional Office for South-East Asia|
|Place of publication:||New Delhi|
|Abstract:||Description: Lymphatic filariasis (LF) is one of the leading causes of permanent disability affecting socioeconomic growth in many LF endemic countries. The WHO South-East Asia Region accounts for the highest burden of LF in 9 of its 11 Member States. The Ninth meeting of the Regional Programme Review Group (RPRG) for Elimination of Lymphatic Filariasis in the South-East Asia Region was held on 30 April to 1 May 2012, in Yangon, Myanmar. The meeting reviewed the progress of LF elimination in the Region, identified major issues and made technical and operational recommendations to scale-up mass drug administration (MDA) and morbidity management in endemic Member States. The meeting while appreciating the progress, approved a total of 710.7 million albendazole treatments for the 2012 MDA round out, of which 457.44 million will be supplied as donation by GSK through WHO. This report presents the synopsis|
|Gov't Doc #:||SEA-CD-261|
|Appears in Collections:||Meeting Reports|
Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated.